140,000 American Lives At Risk -- And This Drug Could Save Them
Portfolio Pulse from Natan Ponieman
Novo Nordisk (NVO) announced that its weight-loss drugs, Wegovy, Ozempic, and Rybelsus, can reduce the risk of heart attack in overweight patients by 20%. This could potentially save 139,400 lives each year in the US. The announcement drove NVO shares up by 16.5%. The company's competitor, Eli Lilly (LLY), also saw its shares climb by 13.9% following the positive results and NVO's announcement. LLY's drug Mounjaro, another GLP-1 drug, is expected to follow Wegovy's path in getting FDA approval for weight loss later this year.
August 08, 2023 | 7:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's shares climbed by 13.9% following the positive results and Novo Nordisk's announcement.
The positive results and Novo Nordisk's announcement about the potential of weight-loss drugs to reduce heart attack risk is likely to have had a positive impact on Eli Lilly's share price, given that it also produces a GLP-1 drug.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Novo Nordisk's announcement about the potential of its weight-loss drugs to reduce heart attack risk drove its shares up by 16.5%.
The announcement about the potential of Novo Nordisk's weight-loss drugs to reduce heart attack risk is a significant positive development for the company, which is likely to have driven the increase in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100